INVENEX PHARMACEUTICALS – Trademark Portfolio

Entity Type: 03

INVENEX PHARMACEUTICALS holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include MURI-LUBE. The owner is based in SAN FRANCISCO 24, CA.

2176 PALOU AVE.

SAN FRANCISCO 24, CA

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

INVENEX PHARMACEUTICALS's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

3
Cosmetics & Cleaning (1 filing)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

Frequently Asked Questions

How many trademarks does INVENEX PHARMACEUTICALS have?

INVENEX PHARMACEUTICALS has 6 U.S. trademarks filed with the USPTO. Of these, 1 registered, 5 cancelled.

What trademark classes does INVENEX PHARMACEUTICALS file in?

INVENEX PHARMACEUTICALS files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are INVENEX PHARMACEUTICALS's most well-known trademarks?

INVENEX PHARMACEUTICALS's registered trademark portfolio includes well-known marks such as MURI-LUBE. These are among 1 currently registered trademark in the portfolio.

What is INVENEX PHARMACEUTICALS's trademark registration success rate?

INVENEX PHARMACEUTICALS has a 17% trademark registration rate, with 1 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.